An observational study in Acute Respiratory Failure, Electrical Impedance Tomography (EIT) and High-Flow Nasal Oxygen Therapy, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Ruijin Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Respiratory Insufficiency with a site in China — 30 open to participants now, 30 under way, 1 of them phase 3. Respiratory Insufficiency · China.
Among the 93 studies in Respiratory Insufficiency with a site in China, this one is the 25th largest by planned enrollment of the 36 observational ones that give a count, is one of 12 that started in 2025, is one of 36 observational ones, reaches primary completion later than 17 of the 29 other live ones, and was the 80th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →30 of the 93 studies in Respiratory Insufficiency with a site in China are open now. Recruiting first, the newest first:
Zhongda Hospital · Sites in China
Ages 18–75
Capital Medical University · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18+
Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2 · Phase 4 4
First in 2007; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 115 is above the median of 100 across 456 observational studies indexed under Respiratory Insufficiency.
Median enrollment 120 across the 57 interventional studies, 175 across the 36 observational. Of the 36 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 93 has an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Ruijin Hospital has 5 studies filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07051980Zhejiang UniversityFeasibility and Safety of Supraglottic Oxygen Delivery Via an Endotracheal Tube for Non-intubated ERCP Anesthesia: A Two-Stage Phase II Clinical Study | 2026-12-02 |
| NCT07372794Capital Medical UniversityEIT-Guided Respiratory Physiotherapy for Prolonged Mechanical Ventilation (PMV) | 2026-12-14 |
| NCT07307066Peking Union Medical College HospitalReal-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study) | 2026-12-30 |
| NCT07366541Ruijin HospitalPredicting High-Flow Nasal Oxygen Failure Within 72 Hours Using a Physiology-Informed Dual-Domain Model at 30 Minutes | 2026-12-31 |
| NCT07898319Ruijin HospitalDevelopment and Prospective Validation of the AutoEIT Foundation Model for ARDS | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 93 studies in Respiratory Insufficiency with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, ambispective observational cohort study of adults with acute hypoxemic respiratory failure (AHRF) receiving high-flow nasal oxygen (HFNO) as initial respiratory support. The study includes three stages. Stage 1 (retrospective derivation): the first 57 consecutive patients (May-September 2025) were retrospectively included to develop and lock a dual-domain logistic model using baseline EFI, baseline PaCO2, and 0-30 minute changes in respiratory rate (ΔRR) and SpO2 (ΔSpO2). Stage 2 (retrospective temporal validation): the later 58 patients (October 2025-March 2026) were retrospectively included, and the frozen model was directly applied without refitting; results of Stages 1 and 2 have been reported. Stage 3 (prospective validation): an independent prospective validation cohort is currently being enrolled, and the frozen model will be applied without refitting. The primary outcome is endotracheal intubation within 72 hours after HFNO initiation. This registration covers the complete study; the retrospective stages have been reported, and the prospective stage is ongoing.
This was a single-center, ambispective observational cohort study conducted at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, between May 2025 and March 2026, with an ongoing prospective validation stage. Adults with AHRF receiving HFNO as initial respiratory support were included. Patients with an immediate indication for endotracheal intubation, severe hemodynamic instability, marked consciousness disturbance or inability to cooperate with monitoring, or missing/inadequate EIT data were excluded. Clinical, physiological, blood gas, and EIT data were collected at baseline before HFNO and at 30 minutes after HFNO initiation. EFI was calculated from the global EIT impedance curve.
Stage 1 (retrospective derivation): the first 57 consecutive patients were included retrospectively; baseline EFI, baseline PaCO2, ΔRR, and ΔSpO2 were used to develop and lock a dual-domain logistic model.
Stage 2 (retrospective temporal validation): the later 58 patients were included retrospectively; the frozen model coefficients were directly applied without refitting. Results of Stages 1 and 2 have been reported.
Stage 3 (prospective validation): an independent multicenter prospective validation cohort is currently being enrolled. The same inclusion/exclusion criteria, 30-minute reassessment protocol, and frozen model will be applied without refitting.
The primary endpoint is endotracheal intubation within 72 hours after HFNO initiation.
The retrospective stages were approved by the Ethics Committee of Ruijin Hospital (Approval No. 2025232), and informed consent was waived. The prospective validation stage was approved by the same committee (Approval No. (2026592), and written informed consent is obtained from all prospectively enrolled participants.
Adult patients with acute respiratory failure receiving HFNO
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First 57 consecutive adults with AHRF receiving HFNO (May-September 2025); used to develop and lock the dual-domain model. Completed.
Other: High-Flow Nasal Oxygen Therapy · Device: Electrical Impedance Tomography Monitoring
Later 58 adults with AHRF receiving HFNO (October 2025-March 2026); frozen model applied without refitting. Completed.
Other: High-Flow Nasal Oxygen Therapy · Device: Electrical Impedance Tomography Monitoring
Independent adults with AHRF receiving HFNO; currently being prospectively enrolled at multiple centers. Frozen model applied without refitting. Ongoing.
Other: High-Flow Nasal Oxygen Therapy · Device: Electrical Impedance Tomography Monitoring
Patients received HFNO as part of standard clinical care for acute hypoxemic respiratory failure. The treatment was titrated by the clinical team based on physiological parameters (SpO2, RR, ABG), aiming to maintain SpO2 ≥ 92% and reduce signs of respiratory distress.
PulmoVista 500 EIT device (Dräger Medical, Lübeck, Germany) was used for continuous real-time monitoring of regional lung ventilation and to derive the EIT-derived flow index (EFI) at baseline and 30 minutes.
HFNO Failure (Endotracheal Intubation Within 72 Hours)
HFNO failure was defined as endotracheal intubation within 72 hours after HFNO initiation due to refractory hypoxemia, progressive respiratory acidosis, severe respiratory distress, or hemodynamic instability. Escalation to noninvasive ventilation (NIV) without endotracheal intubation and within-tier adjustments (increasing flow or FiO2 without changing support modality) were NOT considered the primary failure event. The model is intended for reassessment at 30 minutes, but the outcome is assessed within 72 hours.Unit of Measure: Proportion of participants.
Time frame: Within 72 hours after HFNO initiation.
Model Discrimination in Retrospective Temporal Validation
Area under the receiver operating characteristic curve (AUC) of the frozen dual-domain model for predicting endotracheal intubation within 72 hours in the retrospective temporal validation cohort.Unit of Measure: AUC (dimensionless, 0-1).
Time frame: Within 72 hours after HFNO initiation.
Model Calibration in Retrospective Temporal Validation
Calibration intercept and slope of the frozen dual-domain model in the retrospective temporal validation cohort. Unit of Measure: Dimensionless.
Time frame: Within 72 hours after HFNO initiation.
Model Discrimination in Prospective Validation
AUC of the frozen dual-domain model for predicting endotracheal intubation within 72 hours in the ongoing prospective validation cohort.Unit of Measure: AUC (dimensionless, 0-1).
Time frame: Within 72 hours after HFNO initiation.
Model Calibration in Prospective Validation
Calibration intercept and slope of the frozen dual-domain model in the ongoing prospective validation cohort. Unit of Measure: Dimensionless.
Time frame: Within 72 hours after HFNO initiation.
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.
Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 19 months is below that.
Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Mar 2026 → Dec 2026 and completion Mar 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.